|
Name |
2,4,8-Trihydroxy-1-tetralone
|
| Molecular Formula | C10H10O4 | |
| IUPAC Name* |
2,4,8-trihydroxy-3,4-dihydro-2H-naphthalen-1-one
|
|
| SMILES |
C1C(C2=C(C(=CC=C2)O)C(=O)C1O)O
|
|
| InChI |
InChI=1S/C10H10O4/c11-6-3-1-2-5-7(12)4-8(13)10(14)9(5)6/h1-3,7-8,11-13H,4H2
|
|
| InChIKey |
FHAMKLIXDLEUPK-UHFFFAOYSA-N
|
|
| Synonyms |
2,4,8-Trihydroxy-1-tetralone; C09974; ACMC-1BQZF; AC1L9D1W; 2,4,8-trihydroxytetralone; SureCN4740190; CHEBI:901; 2,4,8-trihydroxy-3,4-dihydro-2H-naphthalen-1-one; SCHEMBL4740190; 2,4,8-trihydroxytetralin-1-one; DTXSID101008561; 2,4,8-Trihydroxy-3,4-dihydronaphthalen-1(2H)-one; 3,4-Dihydro-2,4,8-trihydroxy-1(2H)-naphthalenone; Q27105377
|
|
| CAS | 88899-02-9 | |
| PubChem CID | 442545 | |
| ChEMBL ID | NA |
Chemical Classification: |
|
|
|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
| Molecular Weight: | 194.18 | ALogp: | 0.6 |
| HBD: | 3 | HBA: | 4 |
| Rotatable Bonds: | 0 | Lipinski's rule of five: | Accepted |
| Polar Surface Area: | 77.8 | Aromatic Rings: | 2 |
| Heavy Atoms: | 14 | QED Weighted: | 0.57 |
| Caco-2 Permeability: | -4.973 | MDCK Permeability: | 0.00000748 |
| Pgp-inhibitor: | 0.001 | Pgp-substrate: | 0.006 |
| Human Intestinal Absorption (HIA): | 0.335 | 20% Bioavailability (F20%): | 0.117 |
| 30% Bioavailability (F30%): | 0.967 |
| Blood-Brain-Barrier Penetration (BBB): | 0.813 | Plasma Protein Binding (PPB): | 37.79% |
| Volume Distribution (VD): | 0.943 | Fu: | 65.29% |
| CYP1A2-inhibitor: | 0.064 | CYP1A2-substrate: | 0.099 |
| CYP2C19-inhibitor: | 0.035 | CYP2C19-substrate: | 0.263 |
| CYP2C9-inhibitor: | 0.015 | CYP2C9-substrate: | 0.855 |
| CYP2D6-inhibitor: | 0.014 | CYP2D6-substrate: | 0.313 |
| CYP3A4-inhibitor: | 0.008 | CYP3A4-substrate: | 0.165 |
| Clearance (CL): | 7.363 | Half-life (T1/2): | 0.669 |
| hERG Blockers: | 0.021 | Human Hepatotoxicity (H-HT): | 0.061 |
| Drug-inuced Liver Injury (DILI): | 0.319 | AMES Toxicity: | 0.339 |
| Rat Oral Acute Toxicity: | 0.558 | Maximum Recommended Daily Dose: | 0.012 |
| Skin Sensitization: | 0.139 | Carcinogencity: | 0.121 |
| Eye Corrosion: | 0.004 | Eye Irritation: | 0.443 |
| Respiratory Toxicity: | 0.13 |
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC006049 | ![]() |
0.727 | D0S0LZ | ![]() |
0.284 | ||
| ENC006048 | ![]() |
0.727 | D07HBX | ![]() |
0.275 | ||
| ENC004790 | ![]() |
0.583 | D08NQZ | ![]() |
0.271 | ||
| ENC003267 | ![]() |
0.583 | D0H1AR | ![]() |
0.258 | ||
| ENC002593 | ![]() |
0.583 | D0J2NK | ![]() |
0.253 | ||
| ENC005843 | ![]() |
0.583 | D08QJS | ![]() |
0.244 | ||
| ENC005067 | ![]() |
0.583 | D0Z1FX | ![]() |
0.244 | ||
| ENC005241 | ![]() |
0.574 | D04QZD | ![]() |
0.243 | ||
| ENC004791 | ![]() |
0.574 | D01WJL | ![]() |
0.241 | ||
| ENC002027 | ![]() |
0.574 | D0C4YC | ![]() |
0.241 | ||